Recruiting

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

ClinicalTrials.gov IDNCT03648814
PhaseNA
Enrollment40
SponsorPrince of Songkla University
Age18 Years and older
SexALL
I'm interested View official listing

Conditions studied

Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression

About this study

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: 1. Diagnosis of neovascular glaucoma 2. The patients having IOP \> 21 mmHg, having the indication for trabeculectomy 3. The patients' age of at least 18-year-old 4. The patients having visual potential at least hand motion. 5. Present of NVI or NVA. 6. Willing and able to provide informed consent to participate in the study 7. Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits Exclusion Criteria: 1. One eye patient 2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view. 3. Cannot obtain endothelial cell count. 4. History of bevacizumab or fluorescence dye allergy. 5. Active infectious ocular disease including endophthalmitis and corneal ulcer 6. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension 7. Has or planning to be pregnant or breastfeeding

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-28.